Bone ultrasound velocity in small- versus appropriate-for-gestational age preterm infants

Chen, M; Ashmeade, Terri; Carver, Jane D.

doi:10.1038/sj.jp.7211769

Cited by 7 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… Littner et al [ 34 ] 2005 Omnisense 7000P Tibia/SOS SGA infants have higher SOS values than AGA controls. Chen et al [ 36 ] 2007 Omnisense 7000P Tibia/SOS Preterm SGA infants had higher tibial SOS values than their AGA counterparts; findings were similar regardless of the reference chart used to categorize infants as SGA or AGA. SOS speed of sound, US ultrasonography …”

Section: Discussionmentioning

confidence: 99%

Feasibility of quantitative ultrasonography for the detection of metabolic bone disease in preterm infants — systematic review

2018

View full text Add to dashboard Cite

Metabolic bone disease of prematurity is characterised by disordered bone mineralisation and is therefore an increased fracture risk. Preterm infants are especially at risk due to incomplete in utero bone accretion during the last trimester. Currently, diagnosing metabolic bone disease mainly relies on biochemistry and radiographs. Dual-energy x-ray absorptiometry and quantitative ultrasound (US) are used less frequently. However, biochemical measurements correlate poorly with bone mineralisation and although scoring systems exist for metabolic bone disease, radiographs are subjective and do not detect early features of osteopenia. Dual energy x-ray absorptiometry is the reference standard for determining bone density in older children and adults. However, challenges with this method include movement artefact, difficulty scanning small and sick infants and a lack of normative data for young children. Quantitative US has a relatively low cost, is radiation-free and portable, and may hence be suitable for assessing bone status in preterm infants. This review aims to provide an overview of the use of quantitative US in detecting metabolic bone disease in preterm infants.Electronic supplementary materialThe online version of this article (10.1007/s00247-018-4161-5) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Feasibility of quantitative ultrasonography for the detection of metabolic bone disease in preterm infants — systematic review

2018

View full text Add to dashboard Cite

show abstract

“…In children born SGA with short stature, low muscle mass may be associated with changes in bone geometry; as assessed by peripheral quantitated computed tomography (pQCT), total bone area, cortical area, cortical thickness, strength-strain index and muscle area were significantly lower than normal references, suggesting impaired bone strength [81]. Impaired bone mineralization has been reported in one study (n = 18) [82] and higher bone strength in another study (n = 31) [83] of SGA infants, in particular those born preterm. Lower bone accretion in preterm infants born SGA than in infants born AGA, independent of body size, suggest that prenatal conditions for bone accretion may not be replicated postnatally [84].…”

Section: Bone Strengthmentioning

confidence: 96%

What is the evidence for beneficial effects of growth hormone treatment beyond height in short children born small for gestational age? A review of published literature

Darendelıler

Kandemir

Harris

et al. 2019

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

BackgroundAn increasing body of evidence supports the view that both an adverse intrauterine milieu and rapid postnatal weight gain in children born small for gestational age (SGA) contribute towards the risk for the development of chronic diseases in adult life.ContentThe aim of this review was to identify and summarize the published evidence on metabolic and cardiovascular risk, as well as risk of impaired cardiac function, intellectual capacity, quality of life, pubertal development and bone strength among children born SGA. The review will then address whether growth hormone (GH) therapy, commonly prescribed to reduce the height deficit in children born SGA who do not catch up in height, increases or decreases these risks over time.SummaryOverall, there are limited data in support of a modest beneficial effect of GH therapy on the adverse metabolic and cardiovascular risk observed in short children born SGA. Evidence to support a positive effect of GH on bone strength and psychosocial outcomes is less convincing.OutlookFurther evaluation into the clinical relevance of any potential long-term benefits of GH therapy on metabolic and cardiovascular endpoints is warranted.

show abstract

“…According to some data, preterm neonates having rickets register a higher ALP level compared to control (952.2+413.8 vs 524.7+158.2 IU/L) [19]. In another study, it was described that increase ALP signifies increased bone osteoblastic activity in preterm babies [27]. Also other researchers have suggested to prevent increase ALP by supplementing the preterm with appropriate minerals [28].…”

Section: Discussionmentioning

confidence: 99%

Osteopenia of prematurity: Assessment of Biochemical parameters in Very low birth weight preterm neonates

2016

View full text Add to dashboard Cite

Background: Osteopenia of prematurity, commonly called as metabolic bone disease (MBD), is mostly described in preterm babies (< 36weeks) with very low birth weight (VLBW). This condition is characterized by a reduction in bone mineral content (osteopenia), with or without rachitic changes, and is caused by several nutritional and biomechanical factors. Objective: To determine the incidence of osteopenia of prematurity among high risk preterm VLBW babies and also to document changes in biochemical parameters including serum calcium, serum phosphate, serum alkaline phosphate (ALP) and serum creatinine in the above cases. Material and method: This prospective observational study includes all the very low birth weight babies born fromNovember 2012 to July 2014. Present study comprised of 60 VLBW neonates of which 10 were <28weeks, 32 were 28-31week and 18 were 31-34weeks of gestation. Estimations of biochemical parameters were done at 2 nd week of birth and again at 6 th week to detect the incidence of osteopenia. Result: There was a significant decrease inserum calcium and serum phosphorous level where asserum ALP documented a significant increase in preterm neonates when compared to control. 14 of 60 VLBW babies developed osteopenia of prematurity at 6 th week of life. Conclusion: As observed in the present study, gestational age, birth weight and ALP are considered to be significant risk factors and are associated with osteopenia. So early detection of this condition by monitoring of biochemical parameters in high-risk cases minimizes the development of osteopeniaand prevent future complications of osteopenia.

show abstract

Bone ultrasound velocity in small- versus appropriate-for-gestational age preterm infants

Cited by 7 publications

References 40 publications

Feasibility of quantitative ultrasonography for the detection of metabolic bone disease in preterm infants — systematic review

Feasibility of quantitative ultrasonography for the detection of metabolic bone disease in preterm infants — systematic review

What is the evidence for beneficial effects of growth hormone treatment beyond height in short children born small for gestational age? A review of published literature

Osteopenia of prematurity: Assessment of Biochemical parameters in Very low birth weight preterm neonates

Contact Info

Product

Resources

About